Aviscumine

Drug Profile

Aviscumine

Alternative Names: BA503; CY-503; ME-503; Mistletoe lectin recombinant; Recombinant mistletoe lectin; Recombinant viscumin; Recombinant viscumine; rViscumin; Viscum ribosome inactivating protein

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VISCUM AG
  • Developer MELEMA Pharma GmbH
  • Class Antineoplastics; Biological toxins; Lectins; Plant proteins
  • Mechanism of Action 28S ribosomal RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Malignant melanoma

Most Recent Events

  • 16 Apr 2016 Phase II development for aviscumine is ongoing in Germany and Autria
  • 16 Apr 2016 Final Efficacy data from a phase II trial in Melanoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR -2016)
  • 31 Aug 2012 Cytavis Biopharma terminates a phase II trial in Colorectal cancer (metastatic disease, second-line or greater therapy) in Germany and Austria due to poor recruitment (NCT00932724)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top